An optimized peptide mapping protocol keeps hydrophobic drug-loaded fragments visible in mass spectrometry, improving antibody-drug conjugate analysis.
14+ ADCsFDA-approved cancer drugs that depend on accurate conjugation site analysis like this method provides
What the researchers found
The protocol addresses a technical challenge in ADC development: hydrophobic drug-loaded peptides tend to precipitate out of solution during standard peptide mapping, making them invisible to mass spectrometry.
The improved method includes modifications to sample preparation that keep hydrophobic drug-loaded peptides dissolved, enables better chromatographic separation so these peptides are not lost, and uses diagnostic fragmentation ions from the drug payload to unambiguously identify conjugation sites in the LC-MS/MS data.
This allows researchers to map exactly which amino acids on the antibody have drugs attached, which is critical for understanding ADC potency and safety.
Why it matters
Antibody-drug conjugates are a growing class of cancer drugs (14+ FDA-approved as of 2024). Where the drug attaches to the antibody affects how well the ADC works and how toxic it is. Accurate conjugation site mapping is essential for ADC quality control and development. This improved protocol solves a real analytical problem.
The numbers in context
LC-MS/MS-based; improved hydrophobic peptide handling; diagnostic fragmentation ion identification
How the study worked
Methods paper describing a peptide mapping protocol. Monoclonal antibodies with drug-linker conjugates are enzymatically digested into peptide fragments, separated by liquid chromatography, and analyzed by tandem mass spectrometry (LC-MS/MS). The paper covers sample preparation, LC-MS/MS setup, and both automated and manual data processing.
Who was studied
Analytical protocol (no clinical subjects)
What this study cannot tell us
This is a methods paper, not a discovery study. It describes a protocol but does not compare its performance quantitatively to other methods. The applicability to different ADC types with different linker chemistries would need to be validated case by case.
How to read the evidence
Moderate evidence. Methods paper describing an optimized analytical protocol with practical validation.
When this study was published
Published in 2020. ADC technology continues to evolve rapidly with new linker and payload chemistries.
The bigger picture
With 14+ FDA-approved ADCs and dozens more in development, accurate conjugation site analysis is critical for the entire cancer drug class. This method supports quality control and design optimization across the ADC field.
Questions still open
- Can this method be adapted for next-generation ADC linker chemistries?
- How does conjugation site variability affect ADC efficacy and toxicity?
- Could automated software replace manual data processing?
Common questions
What is an antibody-drug conjugate?
Why does it matter where the drug attaches?
Read the original research
Conjugation Site Analysis by MS/MS Protein Sequencing.
Methods in molecular biology (Clifton, N.J.), 2078, 221-233
Citation
Han, Linjie; Zhao, Yanqun; Zhang, Qunying. (2020). Conjugation Site Analysis by MS/MS Protein Sequencing.. Methods in molecular biology (Clifton, N.J.), 2078, 221-233. https://doi.org/10.1007/978-1-4939-9929-3_15